Purpose

This research is a prospective study in which the purpose is to investigate the clinical outcomes following the transfer of a mosaic embryo (presence of both chromosomally normal and abnormal cells) that has been screened for preimplantation genetic testing (PGT).

Condition

Eligibility

Eligible Ages
Between 18 Years and 45 Years
Eligible Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Women age 18-45 Infertile women who have completed an IVF cycle with PGT at the Colorado Center for Reproductive Medicine (CCRM) that have a mosaic embryo - Patients can be of any race, culture, sexual orientation or ethnicity - Patients that are willing to transfer a single embryo

Exclusion Criteria

  • Patients that do not meet the clinical requirements for an embryo transfer per clinic standards. - Patients that desire more than a single embryo transfer. - Patients that are using a gestational carrier. - Embryonic mosaic PGT results that include chromosome errors 13, 18, 21 - Patients that did not complete their IVF with PGT cycle at the Colorado Center for Reproductive Medicine.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Intervention Model Description
Outcomes will be evaluated with women who have a mosaic embryo transferred
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Transfer of mosaic embryo
Women will have a mosaic embryo transferred to their uterus after in vitro fertilization (IVF) with pre implantation genetic testing completed at Colorado Center for Reproductive Medicine.
  • Procedure: Transfer of mosaic embryo
    Subjects will transfer a mosaic embryo transferred to their uterus

Recruiting Locations

Colorado Center for Reproductive Medicine
Lone Tree, Colorado 80124
Contact:
Rachel Makloski, RN
TriggerStudy@colocrm.com

More Details

NCT ID
NCT04472156
Status
Recruiting
Sponsor
Colorado Center for Reproductive Medicine

Study Contact

Rachel Makloski, RN
303-788-8300
rmakloski@colocrm.com

Detailed Description

This research is a prospective study with the purpose is to investigate the clinical outcomes following the transfer of a mosaic embryo (presence of both chromosomally normal and abnormal cells) that has been screened for preimplantation genetic testing (PGT). PGT involves the biopsy and testing of a handful (3-6) of trophectoderm (pre-placental cells) from the embryo. Embryos that are screened as mosaic via PGT, as a standard, are not offered for transfer for pregnancy attempt. Publications have shown that mosaic embryos and mosaic fetuses can result in healthy live births (Wallerstein et al, 2015; Victor et al, 2019). Ongoing clinical outcomes are important to further understand the association between an embryonic mosaic biopsy of pre-placental cells and subsequent fetal chromosomal constitution. Implantation rates and live birth rates will be evaluated to help understand if mosaic embryos should routinely be offered for transfer to patients attempting pregnancy.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.